Pardes Biosciences

Acquired

Clinical-stage biopharmaceutical company that developed novel oral antiviral therapeutics targeting COVID-19. Went public via SPAC merger in 2021 before being acquired by MediPacific (a Foresite Capital affiliate) in 2023 after its lead candidate failed Phase 2 trials.

Founders Uri Lopatin

CEO Uri Lopatin

Company

Founded

2020

Headquarters

Carlsbad, US

Employees

51-200

Financials

Total Funding

$127M

Revenue (ARR)

pre-revenue

Sectors

Biotech

www.pardesbio.com

Funding History

3 rounds

Acquired by MediPacific Aug 31, 2023

$130M

Undisclosed Dec 27, 2021

$75M

Foresite Capital (Lead) RA Capital Management Frazier Healthcare Partners T. Rowe Price GMF Capital EcoR1 Capital Monashee Investment Management Gilead Sciences

Series C Feb 3, 2021

$52M

Foresite Capital (Lead) Khosla Ventures GMF Capital Frazier Healthcare Partners Olive Capital

Seed Jun 1, 2020

$125K

Y Combinator (Lead)

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.